Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
ARK Invest Catherine D. Wood | “Alamar Biosciences develops high-sensitivity life science tools and consumables focused on precision proteomics. Its proprietary NULISA platform detects extremely low-abundance proteins and neurological biomarkers in biofluids. The manager initiated a position representing 1.06% of ARKG, highlighting the firm as an indispensable enabler in the broader multiomics revolution. Alamar's economic model relies on a classic razor-and-blade commercial structure. As academic institutions and biopharmaceutical companies install NULISA instrumentation, Alamar secures recurring, high-margin revenue streams through proprietary assay consumable panels. The extreme sensitivity of NULISA generates high switching costs and pricing power in translational drug development, driving superior return on invested capital as customer adoption deepens across neuroscience, oncology, and immunology. Key catalysts include commercial rollouts of targeted disease panels in oncology and cardiovascular medicine, accompanied by expanding biopharma diagnostic partnerships. Primary risks include clinical adoption delays, prolonged enterprise sales cycles among academic labs, and intense competition from incumbent immunoassay providers.” | BULL | Q2 2026 Jun 30, 2026 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
